Biolex Therapeutics Announces Agreement With Genmab, Inc. for New Class of Antibodies

Published: May 07, 2007

PITTSBORO, NC -- (MARKET WIRE) -- May 07, 2007 -- Biolex Therapeutics today announced an agreement with Genmab A/S, a leading antibody development company. Under the agreement Genmab will evaluate Biolex's patented LEX System(SM) as a potential manufacturing platform for antibodies developed with UniBody™, Genmab's proprietary new antibody technology.

Back to news